AbCellera Results Presentation Deck

FINANCIALS Q3 2021 BUSINESS UPDATE COPYRIGHT © ABCELLERA 15 Five molecules in the clinic, over a dozen in preclinical development. MOLECULE bamlanivimab (LY-CoV555) bebetelovimab (LY-CoV1404) NBL-012 NBL-015 IVX-01 STAGE Marketed, Emergency Use Authorization (EUA) Phase II Phase I IND approved Clinical field study PARTNER Lilly Lilly NovaRock BIOTHERAPEUTICS NovaRock BOTHERAPEUTICS Invetx THERAPEUTIC AREA COVID-19 ● COVID-19 • dermatology gastrointestinal disease • immunology oncology animal health PROGRAM TYPE AbCellera Discovery Partnership Trianni License AbCellera Discovery Partnership

View entire presentation